Study Title
FAPi Radioligand Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Dosimetry of [Lu-177]-PNT6555; A Dose Escalation Study for Treatment of Patients With Select Solid Tumors (FRONTIER)
Study Details
Description:
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
Sponsor:
Point BiopharmaGovernment Study Link:
NCT05432193 - Click here to see study onClinicalTrials.gov
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations